Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMP | P19971 | 1/20 | 0.38 |
| ▸ | PYGM | P11217 | 3/20 | 0.36 |
| ▸ | TK2 | O00142 | 2/20 | 0.33 |
| ▸ | CDA | P32320 | 2/20 | 0.33 |
| ▸ | SLC5A2 | P31639 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5966133 | 0.84 | PYGM (0.41) | TYMPPYGMTK2CDASLC5A2 | |
| SCHEMBL9092454 | 0.65 | TYMP (0.41) | TYMPPYGMMAPT | |
| SCHEMBL31685557 | 0.64 | SLC5A2 (0.38) | SLC5A2 | |
| SCHEMBL10387877 | 0.63 | TYMP (0.59) | TYMPPYGMTK2 | |
| SCHEMBL9159942 | 0.63 | TYMP (0.59) | TYMPPYGMTK2 | |
| SCHEMBL10890226 | 0.63 | TYMP (0.59) | TYMPPYGMTK2 | |
| SCHEMBL9159931 | 0.63 | TYMP (0.59) | TYMPPYGMTK2 | |
| SCHEMBL10387879 | 0.63 | TYMP (0.59) | TYMPPYGMTK2 | |
| SCHEMBL15511208 | 0.63 | PYGM (0.66) | PYGMTK2MAPT | |
| SCHEMBL18573960 | 0.63 | SLC5A2 (0.44) | CDASLC5A2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7118731-B2 | Drugs for the diagnosis of tissue reproductive activity or the treatment of proliferative diseases | NIHON MEDI-PHYSICS CO., LTD. (JP) | 2006-10-10 | — | — | US | disclosed |
| US-7045115-B2 | Drugs for the diagnosis of tissue-reproductive activity or the treatment of proliferative diseases | NIHON MEDI-PHYSICS CO., LTD. (JP) | 2006-05-16 | — | — | US | disclosed |
| EP-1270017-B1 | RADIOLABELED PYRIMIDINE NUCLEOSIDE FOR THE DIAGNOSIS OF TISSUE-REPRODUCTIVE ACTIVITY | NIHON MEDIPHYSICS CO LTD (JP) | 2006-04-12 | — | — | EP | disclosed |
| US-20050129611-A1 | Antitumor agents; anticancer agents; viricides; nucleoside derivative | NIHON MEDI-PHYSICS CO., LTD. (JP) | 2005-06-16 | — | — | US | disclosed |
| US-20030124054-A1 | Drugs for the diagnosis of tissue-reproductive activity or the treatment of proliferative diseases | NIHON MEDI-PHYSICS CO., LTD. (JP) | 2003-07-03 | — | — | US | disclosed |
| EP-1270017-A1 | DRUGS FOR THE DIAGNOSIS OF TISSUE-REPRODUCTIVE ACTIVITY OR THE TREATMENT OF PROLIFERATIVE DISEASES | Nihon Medi-Physics Co., Ltd. (JP) | 2003-01-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030124054-A1 | Drugs for the diagnosis of tissue-reproductive activity or the treatment of proliferative diseases | MKI67, PCNA, NR5A1 | TYMP 100/4885PYGM 1489/4885TK2 16/4885 |
| US-20050129611-A1 | Antitumor agents; anticancer agents; viricides; nucleoside derivative | MKI67, SNRPD1, TK1 | TYMP 29/4885PYGM 2503/4885TK2 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.